Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bill Frame

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of Clinical Pharmacology|October 1, 2010
Population pharmacokinetic-pharmacodynamic modeling of biological agents: when modeling meets realityDiane R Mould, Bill Frame
Journal of Pharmacokinetics and Pharmacodynamics|November 12, 2009
Joint modeling of dizziness, drowsiness, and dropout associated with pregabalin and placebo treatment of generalized anxiety disorderBill Frame, Raymond Miller, Matthew M Hutmacher
Journal of Pharmacokinetics and Pharmacodynamics|October 24, 2003
Evaluation of mixture modeling with count data using NONMEMBill Frame, Raymond Miller, Richard L Lalonde
Journal of Clinical Pharmacology|July 29, 2010
Modeling dropout from adverse event data: impact of dosing regimens across pregabalin trials in the treatment of generalized anxiety disorderBojan Lalovic, Matt Hutmacher, Bill Frame, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 27, 2008
An alternative method for population pharmacokinetic data analysis under noncompliancePankaj Gupta, Matthew M Hutmacher, Bill Frame, et al.
Journal of Clinical Pharmacology|June 16, 2015
Exposure-response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin (DS-5565) in patients with diabetic peripheral neuropathic painMatthew M Hutmacher, Bill Frame, Raymond Miller, et al.
Journal of Pharmacokinetics and Pharmacodynamics|August 11, 2007
Mixed effects modeling of weight change associated with placebo and pregabalin administrationBill Frame, Stuart L Beal, Raymond Miller, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 24, 2004
A two-part mixture model for longitudinal adverse event severity dataKenneth G Kowalski, Lynn McFadyen, Matthew M Hutmacher, et al.
Clinical Pharmacology and Therapeutics|June 18, 2003
Exposure-response analysis of pregabalin add-on treatment of patients with refractory partial seizuresRaymond Miller, Bill Frame, Brian Corrigan, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 7, 2008
Hepatic absorbed radiation dosimetry during I-131 metaiodobenzylguanidine (MIBG) therapy for refractory neuroblastomaKenneth F Koral, John P Huberty, Bill Frame, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of Clinical Pharmacology|October 1, 2010
Population pharmacokinetic-pharmacodynamic modeling of biological agents: when modeling meets realityDiane R Mould, Bill Frame
Journal of Pharmacokinetics and Pharmacodynamics|November 12, 2009
Joint modeling of dizziness, drowsiness, and dropout associated with pregabalin and placebo treatment of generalized anxiety disorderBill Frame, Raymond Miller, Matthew M Hutmacher
Journal of Pharmacokinetics and Pharmacodynamics|October 24, 2003
Evaluation of mixture modeling with count data using NONMEMBill Frame, Raymond Miller, Richard L Lalonde
Journal of Clinical Pharmacology|July 29, 2010
Modeling dropout from adverse event data: impact of dosing regimens across pregabalin trials in the treatment of generalized anxiety disorderBojan Lalovic, Matt Hutmacher, Bill Frame, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 27, 2008
An alternative method for population pharmacokinetic data analysis under noncompliancePankaj Gupta, Matthew M Hutmacher, Bill Frame, et al.
Journal of Clinical Pharmacology|June 16, 2015
Exposure-response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin (DS-5565) in patients with diabetic peripheral neuropathic painMatthew M Hutmacher, Bill Frame, Raymond Miller, et al.
Journal of Pharmacokinetics and Pharmacodynamics|August 11, 2007
Mixed effects modeling of weight change associated with placebo and pregabalin administrationBill Frame, Stuart L Beal, Raymond Miller, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 24, 2004
A two-part mixture model for longitudinal adverse event severity dataKenneth G Kowalski, Lynn McFadyen, Matthew M Hutmacher, et al.
Clinical Pharmacology and Therapeutics|June 18, 2003
Exposure-response analysis of pregabalin add-on treatment of patients with refractory partial seizuresRaymond Miller, Bill Frame, Brian Corrigan, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 7, 2008
Hepatic absorbed radiation dosimetry during I-131 metaiodobenzylguanidine (MIBG) therapy for refractory neuroblastomaKenneth F Koral, John P Huberty, Bill Frame, et al.
Pageof 1